Tc Biopharm Plc Stock Current Valuation
| TCBPW Stock | USD 0.02 0 24.67% |
Valuation analysis of TC BioPharm plc helps investors to measure TC BioPharm's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to drop to -0.0084 in 2024. Enterprise Value Multiple is likely to drop to -0.0084 in 2024.
Overvalued
Today
Please note that TC BioPharm's price fluctuation is out of control at this time. Calculation of the real value of TC BioPharm plc is based on 3 months time horizon. Increasing TC BioPharm's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the TCBPW stock is determined by what a typical buyer is willing to pay for full or partial control of TC BioPharm plc. Since TC BioPharm is currently traded on the exchange, buyers and sellers on that exchange determine the market value of TCBPW Stock. However, TC BioPharm's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0187 | Real 0.0123 | Hype 0.02 |
The intrinsic value of TC BioPharm's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence TC BioPharm's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of TC BioPharm plc helps investors to forecast how TCBPW stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of TC BioPharm more accurately as focusing exclusively on TC BioPharm's fundamentals will not take into account other important factors: TC BioPharm plc Company Current Valuation Analysis
TC BioPharm's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
TCBPW Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for TC BioPharm is extremely important. It helps to project a fair market value of TCBPW Stock properly, considering its historical fundamentals such as Current Valuation. Since TC BioPharm's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of TC BioPharm's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of TC BioPharm's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, TC BioPharm plc has a Current Valuation of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
TC BioPharm plc is currently under evaluation in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 0.0. TC BioPharm adds roughly 0.0 in current valuation claiming only tiny portion of equities under Health Care industry.TCBPW Fundamentals
| Return On Equity | -12.17 | ||||
| Return On Asset | -1.09 | ||||
| Number Of Shares Shorted | 529 | ||||
| EBITDA | (13.61 M) | ||||
| Net Income | (5.91 M) | ||||
| Cash And Equivalents | 1.55 M | ||||
| Cash Per Share | 0.08 X | ||||
| Total Debt | 1.8 M | ||||
| Current Ratio | 0.18 X | ||||
| Book Value Per Share | 3.38 X | ||||
| Cash Flow From Operations | (10.54 M) | ||||
| Earnings Per Share | (0.75) X | ||||
| Number Of Employees | 41 | ||||
| Beta | 0.25 | ||||
| Total Asset | 8.93 M | ||||
| Retained Earnings | (38.84 M) | ||||
| Working Capital | 950.33 K | ||||
| Net Asset | 8.93 M |
About TC BioPharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TC BioPharm plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TC BioPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TC BioPharm plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for TCBPW Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.